Immutep Ltd · ASX:IMM
Immutep — Prima BioMed — Q2 FY2014 Earnings Presentation
5 slides from Immutep's earnings presentation, Feb 6, 2014
Slide 1: 2nd quarter results for FY 2014 – Supplemental information to management discussion
2nd quarter results for FY 2014 (period ended 31 December 2013) Supplemental information to management discussion February 6, 2014 ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034 1 PRIMA BIOMED Important Notice The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 0
Slide 2: CVac CAN-003 Clinical Trial Data / Exciting path forward
CVac™ CAN-003 Clinical Trial Data • CAN-003 data demonstrate a clinically significant and durable improvement in progression-free survival (PFS) for CVac patients versus standard of care (n=20; ovarian patients in second remission) • CAN-003 data presented at European Cancer Congress in October, Soc
Slide 3: CVac in second remission ovarian cancer
CVac in second remission ovarian cancer CAN-003 protocol Kaplan Meier estimates of progression-free survival (PFS) in the intent to treat (ITT) population (20 randomized patients in second complete remission) 5 PRIMA BIOMED 1.0 0.75 0.50 0.25 0.00 0 6 12 18 24 30 Progression Probability Months OSC 6
Slide 4: CAN-004 phase 2 trial and CAN-301 pilot pancreatic cancer trial
CAN-004 phase 2 trial: establish robust proof of concept in ovarian cancer 2 Cohorts 1st Remission 2nd Remission 76 randomized patients; 210 randomized patients; placebo control observation-only control CR after optimal debulking & 1st line Platinum sensitive patients in CR platinum/taxane chemother
Slide 5: CVac clinical trial timetable and financial results for 2nd quarter FY 2014
CVac clinical trial timetable Clinical Quarter (Calendar year basis) Trial 2013 2014 2015 2016 2017 Protocols Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 CAN-003 CAN-003X CAN-004 (1) CAN-004 (2) CAN-301 enrollment period interim OS OS analysis point final treatment period PFS analysis poin